Immunotherapy in Liver Cancer: Overcoming the Tolerogenic Liver Microenvironment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Sep 19

PMID 39295859

Authors

Yanju Liu

Hongyuan Yang

Tian Li

Na Zhang

Affiliations

Soon will be listed here.

Abstract

Liver cancer is a major global health concern, ranking among the top causes of cancer-related deaths worldwide. Despite advances in medical research, the prognosis for liver cancer remains poor, largely due to the inherent limitations of current therapies. Traditional treatments like surgery, radiation, and chemotherapy often fail to provide long-term remission and are associated with significant side effects. Immunotherapy has emerged as a promising avenue for cancer treatment, leveraging the body's immune system to target and destroy cancer cells. However, its application in liver cancer has been limited. One of the primary challenges is the liver's unique immune microenvironment, which can inhibit the effectiveness of immunotherapeutic agents. This immune microenvironment creates a barrier, leading to drug resistance and reducing the overall efficacy of treatment. Recent studies have focused on understanding the immunological landscape of liver cancer to develop strategies that can overcome these obstacles. By identifying the specific factors within the liver that contribute to immune suppression and drug resistance, researchers aim to enhance the effectiveness of immunotherapy. Prospective strategies include combining immunotherapy with other treatments, using targeted therapies to modulate the immune microenvironment, and developing new agents that can bypass or counteract the inhibitory mechanisms in the liver. These advancements hold promise for improving outcomes in liver cancer treatment.

Citing Articles

Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites.

Parrett B, Yamaoka S, Barry M Mol Ther Methods Clin Dev. 2025; 33(1):101402.

PMID: 39867482 PMC: 11758401. DOI: 10.1016/j.omtm.2024.101402.

Targeting ferroptosis: the role of non-coding RNAs in hepatocellular carcinoma progression and therapy.

Wang W, Hashimi B, Wang P Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39820644 DOI: 10.1007/s00210-025-03791-y.

Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis.

Bourguignon L, Hetu-Arbour R, Charpentier T, Bolduc M, Leclerc D, Heinonen K Oncoimmunology. 2024; 13(1):2429846.

PMID: 39552216 PMC: 11581170. DOI: 10.1080/2162402X.2024.2429846.

References

Zhu A, Finn R, Edeline J, Cattan S, Ogasawara S, Palmer D . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19(7):940-952. DOI: 10.1016/S1470-2045(18)30351-6. View

Lin M, He J, Zhang X, Sun X, Dong W, Zhang R . Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma. J Clin Invest. 2023; 133(9). PMC: 10145938. DOI: 10.1172/JCI164528. View

Sun L, Gao F, Gao Z, Ao L, Li N, Ma S . Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. J Immunother Cancer. 2021; 9(4). PMC: 8039282. DOI: 10.1136/jitc-2020-001875. View

Prieto J, Melero I, Sangro B . Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015; 12(12):681-700. DOI: 10.1038/nrgastro.2015.173. View

Ho D, Tsui Y, Chan L, Sze K, Zhang X, Cheu J . Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nat Commun. 2021; 12(1):3684. PMC: 8211687. DOI: 10.1038/s41467-021-24010-1. View

Rebouissou S, Nault J . Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020; 72(2):215-229. DOI: 10.1016/j.jhep.2019.08.017. View

Pinter M, Jain R, Duda D . The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol. 2020; 7(1):113-123. PMC: 8265820. DOI: 10.1001/jamaoncol.2020.3381. View

Wu G, Ma Z, Cheng Y, Hu W, Deng C, Jiang S . Targeting Gas6/TAM in cancer cells and tumor microenvironment. Mol Cancer. 2018; 17(1):20. PMC: 5793417. DOI: 10.1186/s12943-018-0769-1. View

Zhu A, Abbas A, Ruiz de Galarreta M, Guan Y, Lu S, Koeppen H . Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022; 28(8):1599-1611. DOI: 10.1038/s41591-022-01868-2. View

10.

Liu W, Zhou X, Yao Q, Chen C, Zhang Q, Ding K . In situ expansion and reprogramming of Kupffer cells elicit potent tumoricidal immunity against liver metastasis. J Clin Invest. 2023; 133(8). PMC: 10104906. DOI: 10.1172/JCI157937. View

11.

Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

12.

Sharma A, Seow J, Dutertre C, Pai R, Bleriot C, Mishra A . Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell. 2020; 183(2):377-394.e21. DOI: 10.1016/j.cell.2020.08.040. View

13.

Hussain S, Schwank J, Staib F, Wang X, Harris C . TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007; 26(15):2166-76. DOI: 10.1038/sj.onc.1210279. View

14.

Tan J, Fan W, Liu T, Zhu B, Liu Y, Wang S . TREM2 macrophages suppress CD8 T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. 2023; 79(1):126-140. DOI: 10.1016/j.jhep.2023.02.032. View

15.

Yau T, Park J, Finn R, Cheng A, Mathurin P, Edeline J . Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2021; 23(1):77-90. DOI: 10.1016/S1470-2045(21)00604-5. View

16.

Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q . Exploiting innate immunity for cancer immunotherapy. Mol Cancer. 2023; 22(1):187. PMC: 10680233. DOI: 10.1186/s12943-023-01885-w. View

17.

El Zarif T, Nassar A, Adib E, Fitzgerald B, Huang J, Mouhieddine T . Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023; 41(21):3712-3723. PMC: 10351941. DOI: 10.1200/JCO.22.02459. View

18.

Oura K, Morishita A, Tani J, Masaki T . Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci. 2021; 22(11). PMC: 8198390. DOI: 10.3390/ijms22115801. View

19.

Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J . The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer. Adv Sci (Weinh). 2022; 10(5):e2203699. PMC: 9929130. DOI: 10.1002/advs.202203699. View

20.

Cheng A, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021; 76(4):862-873. DOI: 10.1016/j.jhep.2021.11.030. View